Replimune Group Inc’s recently made public that its Director Astley-Sparke Philip unloaded Company’s shares for reported $0.26 million on May 20 ’25. In the deal valued at $8.06 per share,32,279 shares were sold. As a result of this transaction, Astley-Sparke Philip now holds 1,405,071 shares worth roughly $13.36 million.
Then, Xynos Konstantinos sold 7,952 shares, generating $64,093 in total proceeds. Upon selling the shares at $8.06, the Chief Medical Officer now owns 146,933 shares.
Before that, Schwendenman Andrew sold 3,287 shares. Replimune Group Inc shares valued at $26,460 were divested by the Chief Accounting Officer at a price of $8.05 per share. As a result of the transaction, Schwendenman Andrew now holds 68,284 shares, worth roughly $0.65 million.
ROTH MKM initiated its Replimune Group Inc [REPL] rating to a Buy in a research note published on August 28, 2024; the price target was $17. Piper Sandler began covering REPL with “an Overweight” recommendation on November 19, 2021.
Price Performance Review of REPL
On Tuesday, Replimune Group Inc [NASDAQ:REPL] saw its stock fall -3.31% to $9.51. Over the last five days, the stock has lost -6.17%. Replimune Group Inc shares have fallen nearly -21.51% since the year began. Nevertheless, the stocks have risen 0.48% over the past one year. While a 52-week high of $17.00 was reached on 02/21/25, a 52-week low of $6.44 was recorded on 04/09/25.
Levels Of Support And Resistance For REPL Stock
The 24-hour chart illustrates a support level at 9.31, which if violated will result in even more drops to 9.11. On the upside, there is a resistance level at 9.89. A further resistance level may holdings at 10.28.
The most recent change occurred on November 17, 2020 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
